Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA™ by the U.S. FDA

KING OF PRUSSIA, Pa., July 20, 2017 /PRNewswire/ -- Churchill Pharmaceuticals, LLC (Churchill), a privately held company devoted to expanding treatment options...

July 20, 2017

Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate

Click here to view the article.

July 10, 2017

Churchill Pharmaceuticals launches a new updated website with a fresh design

King of Prussia, PA., May 16, 2017 Churchill Pharmaceuticals, a drug development biopharmaceutical company specialized in oral oncology, announced the...

May 22, 2017

Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects, Clinical Pharmacokinetics 2017

Click here to view the article.

May 5, 2017